Pharma Mar SA
Pharma Mar EU Taxonomy Data Preview
In 2024, Pharma Mar was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Pharma Mar has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Pharma Mar are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Eligible A Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Opex | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Eligible A Opex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Opex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Capex | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Eligible A Capex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Taxonomy Non-Eligible B Capex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected EU Taxonomy data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Pharma Mar's Revenues from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible revenues of EUR 66.54 million, representing 38.1% of its total turnover. Of this amount, EUR 0 of Pharma Mar's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
Insights into Pharma Mar's CAPEX from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible CAPEX of EUR 1.02 million, representing 5.8% of its total CAPEX. Of this amount, EUR 85,000 of Pharma Mar's CAPEX was classified as EU Taxonomy-aligned, indicating that 0.5% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
How much of Pharma Mar's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Pharma Mar reported that EUR 1.02 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 5.8% of the company's total CAPEX. Of this amount, EUR 85,000 (0.5% of total CAPEX) was classified as Taxonomy-aligned. This means that 5.3% of Pharma Mar's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).
How much of Pharma Mar's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Pharma Mar reported that EUR 85,000 of its CAPEX was aligned under the EU Taxonomy, representing 0.5% of its total capital investment.
This low alignment reflects that Pharma Mar is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Pharma Mar's Eligibility & Alignment Overview
Pharma Mar's Contribution to Environmental Objectives
- Total Taxonomy Aligned A1 Capex
- Total Taxonomy Eligible but Not Aligned A2 Capex
How is Pharma Mar's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Pharma Mar reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectives:
- Climate Change Mitigation: 0.5%
- Climate Change Adaptation: 0%
- Sustainable Use and Protection of Water and Marine Resources: 0%
- Transition to a Circular Economy: 0%
- Pollution Prevention and Control: 0%
- Protection and restoration of biodiversity and ecosystems: 0%
How much Pharma Mar is investing in climate-related solutions?
In 2024, Pharma Mar allocated EUR 87,810 of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0.5% of the company's total capital expenditure, indicating that Pharma Mar has only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.
Insights into Pharma Mar's OPEX from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible OPEX of EUR 153,000, representing 0.1% of its total operating expenses (OPEX). Of this amount, EUR 3,000 of Pharma Mar's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
Pharma Mar's Contribution to Environmental Objectives
- Total Taxonomy Aligned A1 Opex
- Total Taxonomy Eligible but Not Aligned A2 Opex
How is Pharma Mar's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2024, Pharma Mar reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectives:
- Climate Change Mitigation: 0%
- Climate Change Adaptation: 0%
- Sustainable Use and Protection of Water and Marine Resources: 0%
- Transition to a Circular Economy: 0%
- Pollution Prevention and Control: 0%
- Protection and restoration of biodiversity and ecosystems: 0%
How much of Pharma Mar's operational budget supports climate-related solutions?
In 2024, Pharma Mar allocated EUR 0 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0% of the company's total OPEX, indicating that Pharma Mar has only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.